Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Follow-Up Questions
Who is the CEO of Alvotech SA?
Mr. Robert Wessman is the Executive Chairman of the Board of Alvotech SA, joining the firm since 2019.
What is the price performance of ALVO stock?
The current price of ALVO is $7.94, it has increased 1.59% in the last trading day.
What are the primary business themes or industries for Alvotech SA?
Alvotech SA belongs to Biotechnology industry and the sector is Health Care
What is Alvotech SA market cap?
Alvotech SA's current market cap is $2.4B
Is Alvotech SA a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Alvotech SA, including 2 strong buy, 5 buy, 3 hold, 0 sell, and 2 strong sell
